CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

Ulofey Wigs Revolutionizes Comfort and Customization with Innovative Wig Cap Technology...

Casino Group and H&S Invest Holding plan to open 210...

Ryoku Nail Defense Launches as Dual-Light Laser Wellness Device for Healthier-Looking...

Best LED Anti-Fungal Device: Welnax BioClear Named 2025’s Top At-Home Toenail...

Kewl Interactive Announces Its Creator Studio, a Safe Space for Embracing...

Jada Ramoon Represents Cayman Islands with Grace and Pride During First...

Personal Care Ingredients Market Projected at USD 20.96 Billion by 2032...

Histopathology Equipment Market to Reach $5.1 Billion by 2034, Fueled by...

Peony Blossom Celebration: A Springtime Cultural Gathering Enchants Bulgaria

Hair Growth Supplements Market to be Worth USD 2,581.1 Million by...

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...